The firm's microfluidic-based technology collects and purifies genetic material, causing a complete PCR reaction that identifies diseases in liquid samples.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
The firm's microfluidic based technology collects and purifies genetic material, producing a complete PCR reaction to identify pathogens in liquid samples.
The firm will use the proceeds to develop its cell-sorting technology for cell line development, genomic sample preparation, CRISPR gene editing, and antibody discovery.
Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.
